National Cancer Center

Fujitsu Corporation

Takeda Chemical Industries, Inc.

Japan Health Sciences Foundation

Teruhiko Yoshida

Kazunori Aoki

Hiromi Sakamoto

Koichi Igarashi

Mitsuhiro Azuma

Masaaki Terada

Yoshio Kozai

Michihiko Aki

Kokichi Sugano

Takuya Nagasawa

Mineko Ushiama

Provided is a non-transitory computer-readable storage medium storing a program causing a computer to execute a process, the process including: receiving a first operation that specifies a person symbol from a plurality of person symbols representing persons present in a family tree; displaying a plurality of first candidate person symbols capable of being connected with the person symbol specified by the received first operation by referring to a first storage unit that stores attribute information with respect to each of a plurality of persons; receiving a second operation that selects a first candidate person symbol from the plurality of first candidate person symbols that have been displayed; and displaying the first candidate person symbol selected by the received second operation while the selected first candidate person symbol is being connected with the person symbol specified by the first operation.

Family tree construction supporting method and family tree construction supporting device

The present invention provides a method of immune/gene combination therapy that has an effect of suppressing growth of an intractable solid tumor and is useful for treatment of such a tumor, and a therapeutic composition used for said method.

Method of treating solid tumor

Methods of suppressing growth of pancreatic tumors or cancer cells having a K-ras gene point mutation in a mammal, comprising: administering therapeutically effective amounts of adenoviral vector and antisense K-ras expressing vector to pancreatic cancer cells via intratumoral administration, wherein the adenoviral vector comprises a DNA sequence encoding a human IFN-alpha and operably linked to a promoter, and the pancreatic cancer cells to which the adenoviral vector is administered express the human IFN-alpha; and the antisense K-ras expressing vector comprises an antisense K-ras nucleotide sequence, wherein the antisense K-ras nucleotide sequence is operably linked to a promoter, and the pancreatic cancer cells to which the anti-sense K-ras expressing vector is administered express the antisense K-ras nucleotide sequence; whereby expression of the human IFN-alpha and the antisense K-ras nucleotide sequence suppress growth of pancreatic tumor or cancer cells in the mammal.

Interferon alpha and antisense K-ras RNA combination gene therapy

A deletion type mutein of heparin-binding secretory transforming factor (hst-1) possesses excellent cell growth promoting activity and is stable. The present mutein can therefore be used as a therapeutic medicine such as a healing promoter for burns, wounds, surgical injuries etc.

Deletion muteins of hst-1

Growing community of inventors

Tokyo, Japan

Teruhiko Yoshida